Revealed: 3 Stocks for Potentially Massive Gains
Here is the latest financial fact sheet of VENUS REMEDIES. For more details, see the VENUS REMEDIES quarterly results and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | -4.0 |
No. of shares | m | 11.44 |
% ch week | % | -7.5 |
% ch 1-mth | % | 21.1 |
% ch 12-mth | % | 921.9 |
52 week H/L | Rs | 314.1/28.4 |
No. of Mths Year Ending |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
---|
VENUS REMEDIES EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 358 | 330 | 218 | 143 | 126 | |
Low | Rs | 140 | 103 | 82 | 65 | 61 | |
Sales per share (Unadj.) | Rs | 473.4 | 405.6 | 365.6 | 324.2 | 301.8 | |
Earnings per share (Unadj.) | Rs | 56.2 | 4.5 | 1.5 | -13.8 | -24.9 | |
Diluted earnings per share | Rs | 56.2 | 4.5 | 1.5 | -14.9 | -26.8 | |
Cash flow per share (Unadj.) | Rs | 91.4 | 44.7 | 37.9 | 18.8 | 2.5 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Dividend yield (eoy) | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 403.5 | 399.2 | 382.5 | 315.0 | 293.3 | |
Adj. book value per share | Rs | 403.5 | 399.2 | 382.5 | 339.7 | 316.4 | |
Shares outstanding (eoy) | m | 11.44 | 11.44 | 11.44 | 12.34 | 12.34 | |
Bonus/Rights/Conversions | WC | - | - | - | - | ||
Price / Sales ratio | x | 0.5 | 0.5 | 0.4 | 0.3 | 0.3 | |
Avg P/E ratio | x | 4.4 | 47.9 | 101.0 | -7.5 | -3.8 | |
P/CF ratio (eoy) | x | 2.7 | 4.8 | 4.0 | 5.5 | 36.7 | |
Price / Book Value ratio | x | 0.6 | 0.5 | 0.4 | 0.3 | 0.3 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 2,849 | 2,471 | 1,717 | 1,282 | 1,154 | |
No. of employees | `000 | NA | NA | 1.0 | 0.9 | 0.9 | |
Total wages/salary | Rs m | 305 | 324 | 250 | 343 | 393 | |
Avg. sales/employee | Rs Th | NM | NM | 4,100.7 | 4,430.1 | 4,026.1 | |
Avg. wages/employee | Rs Th | NM | NM | 245.3 | 379.5 | 425.0 | |
Avg. net profit/employee | Rs Th | NM | NM | 16.7 | -189.1 | -331.8 |
VENUS REMEDIES INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 5,416 | 4,640 | 4,183 | 4,000 | 3,724 | |
Other income | Rs m | 5 | 7 | 20 | 23 | 23 | |
Total revenues | Rs m | 5,420 | 4,647 | 4,203 | 4,023 | 3,747 | |
Gross profit | Rs m | 1,382 | 892 | 812 | 507 | 395 | |
Depreciation | Rs m | 402 | 460 | 417 | 403 | 338 | |
Interest | Rs m | 294 | 412 | 380 | 344 | 354 | |
Profit before tax | Rs m | 691 | 27 | 35 | -216 | -275 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 48 | -25 | 18 | -46 | 32 | |
Profit after tax | Rs m | 643 | 52 | 17 | -171 | -307 | |
Gross profit margin | % | 25.5 | 19.2 | 19.4 | 12.7 | 10.6 | |
Effective tax rate | % | 6.9 | -94.8 | 51.6 | 21.1 | -11.5 | |
Net profit margin | % | 11.9 | 1.1 | 0.4 | -4.3 | -8.2 |
VENUS REMEDIES BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 2,721 | 2,675 | 2,759 | 2,594 | 2,638 | |
Current liabilities | Rs m | 2,110 | 1,965 | 1,920 | 1,968 | 2,305 | |
Net working cap to sales | % | 11.3 | 15.3 | 20.1 | 15.6 | 8.9 | |
Current ratio | x | 1.3 | 1.4 | 1.4 | 1.3 | 1.1 | |
Inventory Days | Days | 96 | 112 | 125 | 128 | 135 | |
Debtors Days | Days | 44 | 50 | 54 | 43 | 46 | |
Net fixed assets | Rs m | 5,073 | 5,219 | 5,288 | 5,056 | 4,871 | |
Share capital | Rs m | 114 | 114 | 114 | 123 | 123 | |
"Free" reserves | Rs m | 4,450 | 4,445 | 3,883 | 3,763 | 3,496 | |
Net worth | Rs m | 4,616 | 4,567 | 4,376 | 3,887 | 3,619 | |
Long term debt | Rs m | 1,400 | 1,686 | 1,911 | 1,618 | 1,374 | |
Total assets | Rs m | 8,344 | 8,411 | 8,047 | 7,650 | 7,509 | |
Interest coverage | x | 3.3 | 1.1 | 1.1 | 0.4 | 0.2 | |
Debt to equity ratio | x | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | |
Sales to assets ratio | x | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
Return on assets | % | 11.2 | 5.5 | 4.9 | 2.3 | 0.6 | |
Return on equity | % | 13.9 | 1.1 | 0.4 | -4.4 | -8.5 | |
Return on capital | % | 16.4 | 7.0 | 6.6 | 2.3 | 1.6 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 17.0 | 17.7 | 20.5 | 18.4 | 13.9 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 921 | 821 | 858 | 736 | 517 | |
Fx inflow | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx outflow | Rs m | 921 | 822 | 858 | 736 | 517 | |
Net fx | Rs m | -921 | -822 | -858 | -736 | -517 |
VENUS REMEDIES CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 527 | 678 | 469 | 589 | 514 | |
From Investments | Rs m | -947 | -672 | 29 | -183 | -123 | |
From Financial Activity | Rs m | 401 | -14 | -464 | -441 | -387 | |
Net Cashflow | Rs m | -20 | -8 | 35 | -35 | 4 |
Share Holding
|
Company Information
|
CHM: Pawan Chaudhary (MD) | COMP SEC: Neha Kodan | YEAR OF INC: 1989 | BSE CODE: 526953 | FV (Rs): 10 | DIV YIELD (%): - |
Read: VENUS REMEDIES 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: PROCTER & GAMBLE HEALTH ORCHID PHARMA SUVEN LIFE SCIENCES DISHMAN PHARMA ALEMBIC PHARMA
Compare VENUS REMEDIES With: PROCTER & GAMBLE HEALTH ORCHID PHARMA SUVEN LIFE SCIENCES DISHMAN PHARMA ALEMBIC PHARMA
Compare VENUS REMEDIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.
For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More